CN104876879B - 一种bcr-abl激酶抑制剂 - Google Patents

一种bcr-abl激酶抑制剂 Download PDF

Info

Publication number
CN104876879B
CN104876879B CN201510172534.7A CN201510172534A CN104876879B CN 104876879 B CN104876879 B CN 104876879B CN 201510172534 A CN201510172534 A CN 201510172534A CN 104876879 B CN104876879 B CN 104876879B
Authority
CN
China
Prior art keywords
bcr
compound
alkyl
amino
abl kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510172534.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104876879A (zh
Inventor
刘静
刘青松
梁小飞
王蓓蕾
王傲莉
刘晓川
陈程
齐紫平
王文超
赵铮
王黎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hefei Institutes of Physical Science of CAS
Original Assignee
Hefei Institutes of Physical Science of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hefei Institutes of Physical Science of CAS filed Critical Hefei Institutes of Physical Science of CAS
Priority to CN201510172534.7A priority Critical patent/CN104876879B/zh
Priority to PCT/CN2015/081220 priority patent/WO2016165205A1/fr
Publication of CN104876879A publication Critical patent/CN104876879A/zh
Application granted granted Critical
Publication of CN104876879B publication Critical patent/CN104876879B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201510172534.7A 2015-04-14 2015-04-14 一种bcr-abl激酶抑制剂 Active CN104876879B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201510172534.7A CN104876879B (zh) 2015-04-14 2015-04-14 一种bcr-abl激酶抑制剂
PCT/CN2015/081220 WO2016165205A1 (fr) 2015-04-14 2015-06-11 Nouvel inhibiteur de kinase bcr-abl

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510172534.7A CN104876879B (zh) 2015-04-14 2015-04-14 一种bcr-abl激酶抑制剂

Publications (2)

Publication Number Publication Date
CN104876879A CN104876879A (zh) 2015-09-02
CN104876879B true CN104876879B (zh) 2018-05-18

Family

ID=53944596

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510172534.7A Active CN104876879B (zh) 2015-04-14 2015-04-14 一种bcr-abl激酶抑制剂

Country Status (2)

Country Link
CN (1) CN104876879B (fr)
WO (1) WO2016165205A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2019006548A1 (fr) * 2017-07-04 2019-01-10 Trillium Therapeutics Inc. Composés de 2,4-diaminopyrimidine fluorés utilisés en tant qu'inhibiteurs de la tyrosine kinase mer (mertk) et leurs utilisations
CN108103186B (zh) * 2018-02-28 2021-07-02 固安博健生物技术有限公司 诊断类风湿性关节炎和骨关节炎的分子标志物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1842529A (zh) * 2003-08-28 2006-10-04 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
CN1898208A (zh) * 2003-12-25 2007-01-17 日本新药株式会社 酰胺衍生物及医药品
WO2007059157A1 (fr) * 2005-11-14 2007-05-24 Genentech, Inc. Inhibiteurs à base de bisamide du signal hedgehog
CN101023063A (zh) * 2004-07-01 2007-08-22 阿斯利康(瑞典)有限公司 用作抗癌药物的吖嗪－甲酰胺类化合物
CN101080396A (zh) * 2004-10-15 2007-11-28 阿斯利康(瑞典)有限公司 作为B－Raf抑制剂的喹喔啉
WO2008144253A1 (fr) * 2007-05-14 2008-11-27 Irm Llc Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci
CN101522636A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 用作蛋白激酶抑制剂的3-氨基-吡唑-4-酰胺衍生物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1842529A (zh) * 2003-08-28 2006-10-04 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
CN1898208A (zh) * 2003-12-25 2007-01-17 日本新药株式会社 酰胺衍生物及医药品
CN101023063A (zh) * 2004-07-01 2007-08-22 阿斯利康(瑞典)有限公司 用作抗癌药物的吖嗪－甲酰胺类化合物
CN101080396A (zh) * 2004-10-15 2007-11-28 阿斯利康(瑞典)有限公司 作为B－Raf抑制剂的喹喔啉
WO2007059157A1 (fr) * 2005-11-14 2007-05-24 Genentech, Inc. Inhibiteurs à base de bisamide du signal hedgehog
CN101522636A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 用作蛋白激酶抑制剂的3-氨基-吡唑-4-酰胺衍生物
WO2008144253A1 (fr) * 2007-05-14 2008-11-27 Irm Llc Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci

Also Published As

Publication number Publication date
WO2016165205A1 (fr) 2016-10-20
CN104876879A (zh) 2015-09-02
WO2016165205A8 (fr) 2023-03-30

Similar Documents

Publication Publication Date Title
CN104844589B (zh) 一种pi3k激酶抑制剂
WO2017101803A1 (fr) Nouveau double inhibiteur de egfr et de alk
AU2018275277B2 (en) Pharmaceutically acceptable salt of EGFR inhibitor, crystal form thereof, preparation method therefor and application thereof
EP1606289B1 (fr) Derives de carboxamide
CN104936951B (zh) 作为激酶抑制剂的苯并咪唑衍生物
CN104844566B (zh) 一种新型结构的激酶抑制剂
JP4012068B2 (ja) ムスカリンアンタゴニスト
CN114057771B (zh) 大环化合物及其制备方法和应用
MX2011002825A (es) Compuestos heterociclicos de carboxamida.
EP3640248B1 (fr) Dérivés d'aminopyrimidine, leur procédé de préparation et leur utilisation
JP5232143B2 (ja) モチリン受容体アンタゴニストとしてのベンジルピペラジン誘導体
CN1642551A (zh) 组蛋白脱乙酰基酶抑制剂
EP2896620A1 (fr) Composé cyclique hétéroaromatique alcynylique et son application
RU2600928C2 (ru) Цианохинолиновые производные
CN106928231A (zh) 一类新型的egfr野生型和突变型的激酶抑制剂
CN108727363A (zh) 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂
CN101351445A (zh) 作为抗炎或抗过敏剂的二环杂环化合物
CN104876879B (zh) 一种bcr-abl激酶抑制剂
CN107245075A (zh) 2,4,6‑三取代吡啶并[3,4‑d]嘧啶类化合物及其盐和应用
KR20140118575A (ko) 신규한 하이드록사메이트 유도체
CN104250253B (zh) 取代四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
CN109456279B (zh) 噻唑氨基苯甲酰胺乙酸酯衍生物及其用途
CN102656172B (zh) 8-氧代二氢嘌呤衍生物
CA2384018C (fr) Antagonistes muscariniques
CN111606887B (zh) 一种新型激酶抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant